Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.
Year: 2013
Type: conference-abstract
Source: Cancer Research
Authors: Jordi Rodon, Dejan Juric, Ana-Maria Gonzalez-Angulo, Johanna Bendell, Jordan Berlin, Douglas Bootle, Kathlene Gravelin, Alan Huang, Adnan Derti, Joseph Lehar, Jens Würthner, Markus Boehm, Eliezer van Allen, Nikhil Wagle, Levi A. Garraway, Roman Yelensky, Philip J. Stephens, Vincent A. Miller, Robert Schlegel, Cornelia Quadt, José Baselga
Institutions: Vall d'Hebron Hospital Universitari, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Sarah Cannon, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Novartis (Switzerland), Broad Institute, Foundation Medicine (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2068770010